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ABSTRACT
Ischemic stroke is a common complication of infective endocarditis (IE), occurring in 20-40% of left side IE cases. In these 
subsets, anticoagulation therapy may provoke hemorrhagic transformation (HT) of ischemic stroke, and complications of 
this magnitude deteriorate the clinical course for IE patients. However, in cases of IE complicated with a mechanical pros-
thetic valve, the physician can be concerned over the maintenance of anticoagulation due to the risk of thrombotic compli-
cation. According to our retrospective review, HT of ischemic stroke in prosthetic valve endocarditis occurred 13.8% (4/29) 
of the time in a variety of situations. Some of these even arose in patients with a subtherapeutic range of prothrombin time. 
(Korean Circ J 2011;41:490-493)
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Introduction 
In patients with native valve infective endocarditis (IE), an-
ticoagulation is not recommended because its benefits have 
never been convincingly demonstrated.
1)2) On the other hand, 
in prosthetic valve endocarditis (PVE), continuation of anti-
coagulation to prevent thrombotic complications is some-
times recommended.
3) 
However, in specific conditions such as PVE caused by St-
aphylococcus aureus (S. aureus) infections with a recent em-
bolic event in the central nervous system (CNS), the general 
advice is to discontinue all forms of anticoagulation.
4) Since 
S. aureus induced PVE results in a higher overall mortality rate 
than PVE caused by other microorganisms, anticoagulation 
should be discontinued for at least the first two weeks of an-
tibiotic therapy. The causes of death are frequently related to 
CNS complications and in particular, brain hemorrhage. 
The two week period is required for thrombus organization, 
preventing acute hemorrhagic transformation (HT) of embo-
lic lesions. Reintroduction of anticoagulation in these patients 
is recommended with caution, and prothrombin time (PT) 
needs to be monitored carefully.
1) 
HT of acute ischemic stroke is an undesirable complica-
tion that occurs in 2.2-44% of clinical cases and in up to 70% 
of pathologic specimens of stroke.
5)6) The location, size, and 
cause of stroke can influence the development of this complic-
ation and the use of all antithrombotics. Anticoagulant and 
thrombolytic agents especially increase the likelihood of se-
rious HT.
6-8) Management of patients with HT depends on the 
amount of bleeding and symptoms, and may include clot ev-
acuation in deteriorating patients. 
Since HT may aggravate the extent of disability and the ov-
erall prognosis of stroke patients, clinicians have a tendency 
to become ambivalent about the maintenance of anticoagu-
lation in the cases of ischemic stroke in PVE.
9-12) In spite of the 
treatment recommendation on PVE caused by S. aureus, there 
is no general consensus about treatment for different patho-
gens, or when PVE is complicated with ischemic stroke.
13-16) 
Therefore, we investigated the incidence and clinical fea-
tures of HT by reviewing IE cases between 2000 to 2010 and 
evaluated the significance of anticoagulation therapy in PVE 
with ischemic stroke.Jin-Sun Kim, et al.   491
Cases
Case 1 
A 72-year-old woman with a mechanical mitral valve was 
admitted to our institution with symptoms of ongoing fever 
and drowsiness. She had undergone mitral valve replacement 
surgery 16 years ago due to severe rheumatic mitral stenosis. 
Echocardiography revealed vegetation at the mechanical valve 
and her blood culture showed coagulase-negative Staphylo-
coccus species. Brain magnetic resonance imaging (MRI) re-
vealed multiple infarct lesions which were suspected of hav-
ing embolic origin (Fig. 1A and B). Even though the patient 
had previously experienced an embolic stroke, anticoagula-
tion therapy with heparin and warfarin was started and main-
tained, since her initial international normalized ratio (INR) 
was 1.18. On day 9 of hospitalization, when her INR was mea-
sured as 2.24, her mental state changed suddenly and non-
contrast brain computed tomography (CT) was immediately 
performed. The CT revealed HT of the previous infarct lesion 
with a midline shifting effect due to a massive hemorrhage 
(Fig. 1C and D). Due to persistent vegetation and uncontr-
olled fever, the attending physician considered surgical in-
tervention to control her PVE. However, her general condition 
deteriorated rapidly after HT and the risk of surgical mortality 
was too high to attempt the operation. Therefore, she was un-
able to undergo surgical intervention. After that, her fever re-
mained uncontrolled, and she did not recover her mental st-
ate at all. Eventually, on her day 42 of hospitalization, the phy-
sician referred her to the geriatric hospital for the purpose of 
hopeless discharge. 
Case 2
A 58-year-old woman, who had undergone a dual valve re-
placement surgery four years previously, visited the emergen-
cy room with a persistent fever for three days. Initial transtho-
racic echocardiography revealed mobile vegetations at both 
mechanical valves and the blood culture revealed the presence 
of Enterococcus faecalis (E. faecalis). Since her initial INR was 
4.15, higher than the target range, anticoagulation therapy 
was withheld and the INR levels were measured periodically. 
Despite discontinuing anticoagulation, her INR remained hi-
gher than normal, although lower than the therapeutic range. 
On day 14 of hospitalization, INR was 1.93 and a brain CT 
was performed to evaluate the source of a persistent head-
ache which had lasted for a day. The CT revealed acute infarc-
tion with hemorrhage in the right temporoparietal lobe, so 
anticoagulation therapy was witheld. Her blood pressure 
was stable at 110/70 mmHg before and after her headache 
symptoms. Despite the use of the appropriate antibiotics, the 
vegetations persisted after systemic embolization (multiple 
liver, spleen and kidney infarctions were detected by the ab-
dominal CT) and intractable fever continued. Therefore, on 
day 35 of hospitalization, the patient underwent redo-dual 
valve replacement surgery, but on day 3 after the operation, 
she died due to intractable low blood pressure which did not 
respond to any inotropic therapies. 
Case 3 
A 46-year-old woman who had undergone mitral valve re-
placement 23 years previously was admitted to hospital due 
to abdominal pain and drowsiness. Her abdominal CT re-
vealed multiple liver and spleen infarctions and transthoracic 
echocardiography revealed vegetations of the mechanical mi-
tral valve. Blood culture showed the presence of S. aureus. Her 
INR at admission was 1.43 (subtherapeutic level) and blood 
pressure was 108/64 mmHg. Her brain MRI revealed multi-
focal acute infarctions with HT at the bilateral cerebellum and 
occipital area. To prevent the aggravation of HT, anticoagu-
lation was withheld for five weeks and restarted with caution. 
The appropriate antibiotic treatment, considering culture sus-
ceptibility, was maintained for six weeks and her fever had 
subsided two weeks after antibiotics initiation. Six weeks fol-
low-up echocardiography revealed disappearance of the pre-
vious vegetation, so antibiotic therapy was accordingly stopp-
ed. Although her PVE had been treated, the multifocal stroke 
with HT resulted in severe functional disability in walking, st-
anding, manual activity and speech. Thus she needed a further 
hospitalization period of approximately 10 weeks for rehabi-
litation therapy. Although 8 months have passed since her 
Fig. 1. Brain magnetic resonance imaging on day 3 of hospitalizat-
ion revealed multiple acute infarcts on diffusion-weighted images, 
suggesting an embolic origin (A and B). Non-contrast brain comput-
ed tomography on day 10 of hospitalization revealed hemorrhagic 
transformation of the previous embolic infarct at the left temporopa-
rietal area and subfalcial herniation due to the mass effect of the he-
morrhage (C and D).
A  
C  
B  
D  492   Hemorrhagic Transformation of Stroke
discharge, she is still currently undergoing rehabilitation th-
erapy in an outpatient clinic. 
Discussion
We retrospectively reviewed the histories of 259 patients 
who had been admitted to our hospital with IE from January 
2000 to April 2010 (Fig. 2). Among them, 29 patients (11.2%) 
had PVE and 8 (27.6%) of the 29 patients suffered from is-
chemic stroke related to PVE. HT was observed in 4 of the 8 
stroke cases. The presence of ischemic stroke and the develop-
ment of HT were diagnosed by an imaging study in sympto-
matic patients. Since most clinicians did not order brain im-
aging studies at the time when patients showed no symptoms 
for CNS complication, asymptomatic hidden ischemic stroke 
or HT may have been overlooked. 
Differences in clinical features between ischemic stroke with 
or without HT are presented in Table 1 and 2. The mean INR 
was higher in ischemic stroke with HT, but due to the small 
number of cases, was not statistically significant. In-hospital 
mortality was quite high, up to 50% in ischemic stroke with 
HT, and the causative pathogens were diverse both in strokes 
with or without HT (Table 1).
Two out of eight patients passed away and both had HT. 
The causes of death were uncontrolled infection and aggra-
vated heart failure. Five out of eight undertook redo-valve re-
placement surgery due to valve dehiscence, a recurrent em-
bolic event, development of tissue defects via infection prog-
ression, paravalvular leakage, and growth of vegetation in 
spite of optimal antibiotic therapies. Four of these five patients 
were with ischemic stroke only, and the remaining one patient 
was complicated with HT. As mentioned earlier in Case 2, 
this patient passed away three days after the operation due to 
intractable low blood pressure. 
In Case 1, HT aggravated the patient’s general condition 
and made her unable to undergo surgical intervention. Al-
though her initial INR was too low for a mechanical mitral val-
ve, anticoagulation therapy in an embolic stroke may act as an 
aggravating factor for HT. Since the causative pathogen was 
not S. aureus, there was no specific guideline or consensus ab-
out anticoagulation therapy in PVE complicated with em-
bolic stroke for this patient. 
In Case 2, since the initial INR was beyond therapeutic le-
Native valve endocarditis
(n=230)
Ischemic stroke (-)
(n=21)
Ischemic stroke (+)
(n=8)
Hemorrhagic
transformation (-)
(n=4)
Hemorrhagic
transformation (+)
(n=4)
Prosthetic valve endocarditis
(n=29)
Infective endocarditis
(n=259)
Fig. 2. Study flows.
Table 1. Ischemic stroke occurrence in prosthetic valve endocarditis
Patient
age/sex
Location 
of PV
Organism
Day of
stroke*
HT
event
Day 
of HT*
Site of stroke
Plt
(10
3/µL)
INR
BP
(mmHg)
F/72 MV CNSA 1 Yes 3 Lt. parietal  571† 2.24† 150/60
F/46 MV Staphylococcus aureus 2 Yes 2 Multifocal  118† 1.43† 108/64
F/44 MV/AV Culture-negative unknown pathogen 1 Yes 1 Multifocal 423† 8.48† 130/80
F/59 MV/AV Enterococcus faecalis 14 Yes 14 Rt. temporo-parietal  235† 1.93† 110/70
M/43 AV Streptococcus anginosus -6 No - Lt. parietal 313 4.54 108/68
F/47 MV Streptococcus viridans -2 No - Multifocal 202 3.15 120/80
M/54 MV Culture-negative unknown pathogen -2 No - Multifocal 075 1.19 130/50
M/44 AV CNSA 2 No - Lt. frontal  221 2.16 130/80
*Time interval in relation to Day 1, day of hospital admission, †Values which were measured at the day of hemorrhagic transformation detec-
tion. PV: prosthetic valve, AV: aortic valve, MV: mitral valve, HT: hemorrhagic transformation, Plt: platelet count, INR: international normal-
ized ratio, BP: blood pressure, CNSA: coagulase-negative Staphylococcus, Lt: left
Table 2. Clinical features of ischemic stroke with or without hemorrhagic transformation
Ischemic stroke without HT (n=4) Ischemic stroke with HT (n=4)
Mean INR* at stroke 2.76 (1.19-4.54) 3.81 (1.18-8.48)
Mean BP at stroke (mmHg) 122/69.5 124.5/68.5
In-hospital mortality (%) 0 50
Length of hospital stay (day)* 56.5 (39-99) 61.5 (39-116)
*Data expressed as mean (range). HT: hemorrhagic transformation, INR: international normalized ratio, BP: blood pressureJin-Sun Kim, et al.   493
vel, anticoagulation therapy was withheld continuously. Al-
though INR was within subtherapeutic range at the time of 
the embolic stroke, HT occurred concurrently. In this case, E. 
faecalis caused PVE and no anticoagulant was used. There-
fore, the discontinuation of anticoagulation does not seem 
to be enough to prevent the occurrence of HT. 
The last patient’s case (Case 3) was already complicated by 
stroke with HT upon admission, and her initial INR was 1.43 
in spite of oral anticoagulation. In this case, because her INR 
was not high, some factor other than clotting tendency must 
be attributable for HT. Although the causative pathogen was 
S. aureus, since the time of HT was assumed to be earlier than 
admission, it seemed impossible to adjust any risk factors 
that might influence the occurrence of HT.
There are several reports on the effect of anticoagulation 
in neurologic complications of PVE. Davenport and Hart
9) tri-
ed to determine the relationship between anticoagulation th-
erapy and neurologic complication in 61 patients with PVE. 
In his study, 11 patients (18%) suffered an embolic stroke and 
6 patients (8%) suffered brain hemorrhage due to septic ar-
teritis, brain infarction, or undetermined causes. No protec-
tive effect of anticoagulation therapy with warfarin was ob-
served and no specific risk of hemorrhagic stroke was evid-
ent with anticoagulation therapy. However, bioprosthetic val-
ves (25 patients) were included in the analysis, and specific at-
tention to HT in stroke was not given. 
In our series, we have attempted to focus on the develop-
ment of HT and related factors. In summary, the incidence of 
HT was quite high (50%, 4 out of 8 cases of PVE complicated 
by ischemic stroke) and the prognosis was very poor (50% 
mortality, and functional disabilities in survivors). HT was 
observed along with diverse pathogens other than S. aureus. 
Although the number of cases was too small to accurately de-
termine a trend, HT could also occur in patients with sub-
therapeutic INR and normal blood pressure. Thus, at present, 
the prediction and prevention of HT is very challenging. For 
optimal care of PVE patients with ischemic stroke, guidelines 
for anticoagulation therapy should be implemented by con-
ducting further research.
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